Lexicon Pharmaceuticals | LXRX - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Abbott USD 52.06B 69M 2026-03
Acadia Pharmaceuticals USD 1.31B 58.54M 2026-06
Agios Pharmaceuticals USD 1.03B 83.09M 2026-06
Akebia Therapeutics USD 25.02M 2.36M 2026-06
Alnylam Pharmaceuticals USD 1.35B 278.74M 2026-06
AstraZeneca USD 50.3B 2.96B 2026-06
BioMarin Pharmaceutical USD 6.32B 109.58M 2026-06
Coherus Biosciences USD 60.84M 17.78M 2026-06
Eli Lilly USD 33.88B 2.68B 2026-06
Halozyme Therapeutics USD 143.54M 76.09M 2026-06
Illumina USD 2.84B 162M 2026-06
Insmed USD 757.49M 52.64M 2026-06
Ironwood Pharmaceuticals USD -217.14M 44.69M 2026-03
J&J USD 84.97B 3.78B 2026-06
Lexicon Pharmaceuticals USD 202.86M 95.32M 2026-03
MacroGenics USD 42.87M 21.68M 2026-06
MannKind USD -67.2M 8M 2026-06
Merck USD 41.93B 3.94B 2026-06
Moderna USD 6.76B 647M 2026-06
Novartis USD 41.95B 3.02B 2026-06
PTC Therapeutics USD -165.36M 15.1M 2026-06
Puma Biotechnology USD 115.27M 10.55M 2025-09
Sarepta Therapeutics USD 1.53B 22.7M 2026-06
Thermo Fisher Scientific USD 51.93B 1.6B 2026-03
Ultragenyx Pharmaceutical USD -291M 55M 2026-06
United Therapeutics USD 6.4B 499.2M 2026-06
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12